TMC 647055

Drug Profile

TMC 647055

Alternative Names: TMC-647055

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Janssen R&D Ireland
  • Developer Janssen R&D Ireland; Merck & Co
  • Class Antivirals
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 01 Dec 2014 Janssen Pharmaceuticals completes a phase IIa trial in chronic Hepatitis C (combination therapy) in Belgium and Germany (NCT01724086; EudraCT2012-002555-42)
  • 01 Apr 2014 Janssen completes a phase I trial in Healthy volunteers in United Kingdom (NCT02064842)
  • 01 Feb 2014 Janssen R&D Ireland plans a phase I trial for Hepatitis C (in combination with simeprevir, in volunteers) in United Kingdom (NCT02064842)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top